ライフサイエンスコーパス: respiratory

1 diators by mitochondria, yielding an overall respiratory activity comparable to that upon chemical re

2 Treatment induced recovery of respiratory activity normalized these effects, increasin

3 y surfactant (PS) for drug delivery over the respiratory air-liquid interface: the interfacial delive

4 COVID-19 affects primarily the respiratory airways leading to dry cough, fever, myalgia

5 or brain studies, abdominal studies in which respiratory and cardiac motion is visible, and a whole-b

6 by multiple organ failure, especially of the respiratory and cardiovascular systems.

7 its performance in the presence of impaired respiratory and renal functions.

8 suis is divided into asymptomatic carriage, respiratory and systemic strains with distinct genomic s

9 ortality and cause-specific (cardiovascular, respiratory, and non-accidental) mortality.

10 6 (6.71-6.82); all sepsis, 2.63 (2.62-2.65); respiratory arrest (Hierarchical Condition Category 83),

11 3 ng/ml) have significantly shorter times to respiratory arrest compared with wild type, without alte

12 ive model for BPD severity that incorporates respiratory assessments beyond 36 weeks postmenstrual ag

13 lgorithm, capable of continuously monitoring respiratory behaviors.

14 We further show that respiratory burst induces antibiotic tolerance in the sp

15 BZR1 could directly bind to the promoter of RESPIRATORY BURST OXIDASE HOMOLOG 1 (RBOH1), and that RB

16 (killing, phagocytosis, transmigration, and respiratory burst) were used to assess the effects of pr

17 The increased respiratory chain activity is related to the mitochondri

18 tochondrial energy metabolism, including the respiratory chain and each enzymatic step of the tricarb

19 ependent intermediary metabolism rather than respiratory chain defects in the bioenergetic impacts of

20 xplored the structural rearrangements of the respiratory chain in human cell lines depleted of the ca

21 and DMK function predominantly in anaerobic respiratory chains, whereas UQ is the major electron car

22 tory epithelial cells, airway club cells and respiratory ciliated cells as potential reservoirs of th

23 aluate the relative incidence of deaths with respiratory/circulatory deaths in the first year after a

24 We included 162 respiratory/circulatory deaths, of which 36 occurred in

25 ysis, pneumonia was associated (P<0.05) with respiratory comorbidity, tumor site, and neoadjuvant che

26 ression of mutant CCN6 protein and inhibited respiratory complex assembly/activity.

27 late electron fluxes from photosynthetic and respiratory complexes.

28 erone Q(6) from its site of synthesis to the respiratory complexes.

29 , thrombosis, dysregulated inflammation, and respiratory complications.

30 arrying risk genotypes may be susceptible to respiratory consequences from acetaminophen use.

31 We propose that the release of axial respiratory constraints, combined with selection for nov

32 the physiological mechanisms responsible for respiratory control during hypoxia at altitude, by linki

33 Positive bacterial respiratory culture predicted pulmonary dysfunction at d

34 rbon dioxide, and nitric oxide-the three-gas respiratory cycle-that insures adequate oxygen and nutri

35 including 3819 cardiovascular deaths and 761 respiratory deaths.

36 lso relieved rate depression at near-maximal respiratory depressant doses of morphine.

37 nyl- and sufentanil-induced antinociception, respiratory depression, and bradycardia in mice and rats

38 Bursts, which are serial taperings of respiratory depth typically spanning minutes at a time,

39 We summarize the epidemiology of respiratory diphtheria and diphtheria-like illness and d

40 We described respiratory diphtheria cases reported to the National No

41 Aspirin-exacerbated respiratory disease (AERD) is a mechanistically distinct

42 ginally arose as part of a major outbreak of respiratory disease centered on Hubei province, China.

43 Here we show that SARS-CoV-2 causes a respiratory disease in rhesus macaques that lasts betwee

44 e increased risk for hospital admissions for respiratory disease, asthma, and pneumonia peaked at lag

45 he predominant clinical presentation is with respiratory disease, neurological manifestations are bei

46 ARS-CoV-2 replication and develop pronounced respiratory disease, which may more accurately reflect h

47 ) that results in excessive inflammation and respiratory disease, with cytokine storm and acute respi

48 sitization to aspirin in aspirin-exacerbated respiratory disease.

49 Chronic conditions, including cardiac and respiratory diseases and mental health conditions, were

50 ory response/disease, organismal injury, and respiratory diseases and were involved in regulation of

51 pergillosis in COVID-19 patients with severe respiratory distress are being reported, but comprehensi

52 d with perinatal outcome, including hydrops, respiratory distress at birth, need for supplemental oxy

53 3%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events

54 ratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe

55 garding the impact of air pollution on acute respiratory distress syndrome (ARDS) is limited, and mos

56 ) receptor 4 (CXCR4) agonists in a rat acute respiratory distress syndrome (ARDS) model utilizing the

57 ng autopsy from patients who died from acute respiratory distress syndrome (ARDS) secondary to influe

58 EP) in critically ill patients without acute respiratory distress syndrome (ARDS).

59 rom mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS).

60 or progress toward a life-threatening acute respiratory distress syndrome (ARDS).

61 es in a critically ill population with acute respiratory distress syndrome (ARDS).

62 which serves as the first event in the acute respiratory distress syndrome (ARDS).

63 Respiratory Distress Syndrome (RDS) is the commonest dia

64 or sepsis patients with versus without acute respiratory distress syndrome and in relation to complic

65 ical interstitial bilateral pneumonia, acute respiratory distress syndrome and multiorgan dysfunction

66 monstrated good discrimination between acute respiratory distress syndrome and nonacute respiratory d

67 eptococcus coinfection, progressing to acute respiratory distress syndrome and shock.

68 na virus 2 pneumonia is linked to both acute respiratory distress syndrome and systemic hypercoagulab

69 The 2015 definition for pediatric acute respiratory distress syndrome did not require the presen

70 Our computable phenotype for acute respiratory distress syndrome had good discrimination in

71 atory disease, with cytokine storm and acute respiratory distress syndrome implicated in the most sev

72 Clinician recognition of acute respiratory distress syndrome is associated with both sy

73 Survival from acute respiratory distress syndrome is improving, and outcomes

74 However, acute respiratory distress syndrome often goes unrecognized.

75 Children meeting pediatric acute respiratory distress syndrome oxygenation criteria with

76 e respiratory distress syndrome and nonacute respiratory distress syndrome patients (C-statistic, 0.7

77 y a CT scan in mechanically ventilated acute respiratory distress syndrome patients.

78 elated to sepsis, respiratory failure, acute respiratory distress syndrome, or multiple organ dysfunc

79 CoV-2 predicted the odds of developing acute respiratory distress syndrome, which increased by 62% (C

80 s of sympathetic nervous system activity and respiratory drive.

81 Further, sw/OH/2017 was capable of efficient respiratory droplet transmission from infected pigs to c

82 ad the greatest effect in limiting spread of respiratory droplets, whereas slit-lamp shields and glov

83 dystrophies, which are often accompanied by respiratory dysfunction.

84 irion binding to and subsequent infection of respiratory epithelial cells were increased upon preincu

85 Within the respiratory epithelium, more than one cell type expresse

86 ENV, SARS and MERS CoVs predominantly infect respiratory epithelium, not macrophages.

87 preferentially infect ferret and human nasal respiratory epithelium.

88 rtiles and (1) baseline characteristics, (2) respiratory exacerbations, (3) progression to COPD at 5

89 se (OR, 1.9; 95% CI, 1.1-3.7; P = 0.04), and respiratory failure (OR, 4.7; 95% CI, 1.1-26.3; P = 0.04

90 or is therapeutic in acute hyperinflammatory respiratory failure in COVID-19 patients.

91 bated inpatients with COVID-19 and hypoxemic respiratory failure requiring oxygen supplementation who

92 oped inspiratory stridor and acute hypoxemic respiratory failure shortly after the stent was placed.

93 rly type 2 myocardial infarction, because of respiratory failure with hypoxia and hemodynamic instabi

94 ogistic regression showed increasing odds of respiratory failure with sC5b-9 (odds ratio 31.9, 95% CI

95 ammation (n = 104, 35.6%) related to sepsis, respiratory failure, acute respiratory distress syndrome

96 cted, including data on clinical management, respiratory failure, and patient mortality.

97 s (surgery, sepsis, pneumonia, pneumothorax, respiratory failure, myocardial infarction, thyrotoxicos

98 nt disease characterized by sepsis and acute respiratory failure.

99 end up in interstitial pneumonia and severe respiratory failure.

100 ventilation via endotracheal tube for acute respiratory failure.

101 ssue inflammation with the aim of preventing respiratory failure.

102 of PBP (39.2% versus 27.7%) and with normal respiratory flora (52.0% versus 43.0%) and were less lik

103 otion, swallow function, vocal function, and respiratory function, respectively.

104 Physical therapy did not improve respiratory function.

105 latile anesthetic, fatigue, active time, and respiratory function.

106 o the deterioration of lung architecture and respiratory functions.

107 nea syndrome (OSAS), may cause compromise of respiratory gas exchange during sleep, related to transi

108 ntify a hitherto unknown role for the dorsal respiratory group.

109 c proximity has been associated with adverse respiratory health outcomes.

110 ronment on Asthma and the European Community Respiratory Health Survey) were included.

111 hrough childhood may have lasting effects on respiratory health.Objectives: To investigate lung funct

112 02, respectively) for aTIV vs TIV, while the respiratory hospitalization rate was similar, in a seaso

113 n impairment, and an increased risk of acute respiratory hospitalizations and early death.

114 , and death) due to medically attended acute respiratory illness (MAARI).

115 lt in inappropriate management of paediatric respiratory illness and misdirection of potentially scar

116 form, while children are largely spared from respiratory illness but can develop a life-threatening m

117 Respiratory illness caused by Corynebacterium diphtheria

118 Most cases among residents included respiratory illness consistent with Covid-19; however, i

119 boratory-confirmed viral infection; clinical respiratory illness had inconsistency.

120 HMPV can cause severe respiratory illness in healthy adults and should be cons

121 ean monthly rate of visits related to severe respiratory illness in June through August of 2019 was t

122 Human coronaviruses (hCoVs) cause severe respiratory illness in the elderly.

123 gns and symptoms of diarrheal disease, acute respiratory illness, and anemia.

124 pulmonary health and the prevention of adult respiratory illness.

125 adults hospitalized with influenza and acute respiratory illness.

126 tion, as well as predominant bacteria during respiratory illnesses, and we correlated these with pres

127 d to prevented cases of infant mortality and respiratory illnesses, with a monetized impact of $8.1 m

128 virus (RSV) is a major cause of acute lower respiratory infection (ALRI) in young children aged <5 y

129 amin D status are at increased risk of acute respiratory infection (ARI), randomized controlled trial

130 Furthermore, the severe acute respiratory infection cases with unknown aetiology were

131 ced ability to prevent or treat lethal viral respiratory infection in mice, with increased maturation

132 e epidemiology of hospitalizations for acute respiratory infection or febrile illness (ARFI) and infl

133 ed on a persistent type 2 immune response to respiratory infection with a natural pathogen (Sendai vi

134 n viral pathogen associated with acute lower respiratory infections (ALRIs), with significant childho

135 onaviruses (CoV) that cause mild to moderate respiratory infections (HCoV-229E, HCoV-NL63, HCoV-OC43,

136 Viral respiratory infections are risk factors for cardiovascul

137 d from healthy individuals and patients with respiratory infections before the first outbreak of coro

138 piratory syncytial virus (RSV) causes severe respiratory infections in infants, young children, and t

139 Respiratory infections in the postacute phase of traumat

140 tis may relate to maternal factors and early respiratory infections independent of atopy.

141 S. maltophilia were assessed in experimental respiratory infections of mice.

142 ronaviridae family of viruses that can cause respiratory infections of varying severity.

143 cessary outpatient prescribing against acute respiratory infections, but data are conflicting on sust

144 n and 40 children with unexplained recurrent respiratory infections, revealing age-dependent variatio

145 t to distinguish clinically from other acute respiratory infections.

146 iratory samples from patients suspected with respiratory infections.

147 use silicon multi-electrode arrays to record respiratory local field potentials (rLFPs) from 196-364

148 isease, and sometimes fatal neurological and respiratory manifestations.

149 Persistent respiratory morbidity a priori defined as a respiratory

150 of mechanical ventilation predict persistent respiratory morbidity at follow-up.

151 tem preparations with respect to the ongoing respiratory motor pattern of inspiration (I), post-inspi

152 day of first positive RT-PCR test were upper respiratory (n=32, 68%) and neurologic (n=30, 64%); feve

153 The functional neuroanatomy of the mammalian respiratory network is far from being understood since e

154 vities, which are altered by hypoxia-induced respiratory neuroplasticity.

155 dmission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites

156 considered as a potential cause of community respiratory outbreaks.

157 ogous alpha- and beta-subunits that mediates respiratory oxygen transport and exchange by cooperative

158 The QIAstat-Dx Respiratory Panel (QIAstat-Dx RP) is a multiplex in vitr

159 QIAstat-Dx RP assay to the established ePlex Respiratory Pathogen Panel (RPP) assay, for which we use

160 Median TTR for major respiratory pathogens by organism ranged from 29.2 to 43

161 de that SIM regimes for immunization against respiratory pathogens warrant further study.

162 respiratory morbidity a priori defined as a respiratory PedsQL, a pediatric quality of life measure,

163 xtracorporeal oxygen delivery, increases the respiratory quotient of the native lung and could reduce

164 Inspiratory time and respiratory rate did not improve Vt of any analyzed lung

165 t of the diaphragm, and Vt decreased and the respiratory rate increased significantly from the beginn

166 onary pressure (DeltaPl), expiratory Vt, and respiratory rate were recorded on admission and 2-4 to 1

167 Bronchiolitis is the commonest cause of respiratory related hospital admissions in young childre

168 -1.32; high: aOR=1.62, 95% CI=1.53-1.71] and respiratory-related readmissions [low: aOR=1.10, 95% CI=

169 ly projecting to VLO significantly inhibited respiratory responses evoked by inhalation of the nocice

170 eference Laboratory received 1,267 serum and respiratory samples from 719 critically ill UK patients

171 gen Panel (RPP) assay, for which we used 287 respiratory samples from patients suspected with respira

172 y syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory samples is the standard method for diagnosis

173 Respiratory samples positive for InfA that were collecte

174 Viral culture from respiratory samples was positive for 19 of 74 patients (

175 yndrome is associated with both systemic and respiratory severity of illness and is also associated w

176 her viral loads and were more likely to have respiratory sick visits within 12 months of discharge (O

177 ment represents an effort from editors at 31 respiratory, sleep, and critical care medicine journals

178 Canada using health administrative data and respiratory specimens collected from patients tested for

179 ased >=20% with prone positioning, and their respiratory status after resuming supine positioning.

180 Clinical practices related to respiratory support have changed but significant variati

181 R-EI was associated with LOS and duration of respiratory support.

182 side effects such as tolerance, dependence, respiratory suppression, constipation, and abuse liabili

183 e >5 years (AUC = 0.77), prodromal fever and respiratory symptoms >6 days (AUC = 0.79), and PCT <0.25

184 Children less frequently reported lower respiratory symptoms (age <18: 21%, age 18-49: 60%, age

185 enting with ARI, compared with those without respiratory symptoms (ie, asymptomatic individuals) or h

186 uals with early COPD more often have chronic respiratory symptoms and severe lung function impairment

187 s were frequently asymptomatic (39%) and had respiratory symptoms less often than younger children (2

188 Cases without respiratory symptoms were analyzed to calculate the prop

189 manifestations of COVID-19 are dominated by respiratory symptoms, some patients present other severe

190 Adults develop respiratory symptoms, which can progress to acute respir

191 s from SARS-CoV-2 PCR-negative patients with respiratory symptoms.

192 ital capacity (FEV1:FVC) less than 0.70 with respiratory symptoms.

193 oids, or unscheduled clinical evaluation for respiratory symptoms.

194 (FluA) virus, influenza B (FluB) virus, and respiratory syncytial virus (RSV) (FFABR assay).

195 ion against infection and disease.IMPORTANCE Respiratory syncytial virus (RSV) causes severe respirat

196 Respiratory syncytial virus (RSV) infection in mouse and

197 Respiratory syncytial virus (RSV) is a leading cause of

198 Respiratory syncytial virus (RSV) is a major cause of ac

199 Respiratory syncytial virus (RSV) is the leading global

200 Respiratory syncytial virus (RSV) is the most common vir

201 We administered respiratory syncytial virus (RSV) to 58 volunteers, of w

202 those in humans given inactivated measles or respiratory syncytial virus vaccines.

203 ions of antiviral activity against the human respiratory syncytial virus were carried out for selecte

204 A study of respiratory syncytial virus-A (RSV A) genotype ON1 genet

205 ed robust neutralizing responses against the respiratory syncytial virus.

206 of critically ill patients with Middle East respiratory syndrome (MERS), accounting for time-varying

207 ious outbreaks of SARS-CoV-1 and Middle East respiratory syndrome (MERS), the development of therapeu

208 ut also aided in the control-of severe acute respiratory syndrome (SARS) in 2003(5).

209 n accurately identify the novel severe acute respiratory syndrome (SARS)-related coronavirus (SARS-Co

210 ysregulated immunothrombosis in severe acute respiratory syndrome corona virus 2 pneumonia is linked

211 d viruses including SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).

212 ased serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) ant

213 York State had 180,458 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,38

214 usion between a new pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and an e

215 n the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the

216 ased drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are bein

217 Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on

218 sease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged

219 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged

220 The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elic

221 The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reac

222 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resu

223 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spre

224 r detecting past infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have man

225 dates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an ol

226 to define previous exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in popul

227 2019 (COVID-19) or detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the e

228 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectio

229 characterizes the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectio

230 ngle specimen type detected all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectio

231 natural history of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectio

232 and number of introductions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into Sco

233 sease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerg

234 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initi

235 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is respo

236 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the c

237 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the c

238 ns in the future.IMPORTANCE The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the e

239 ptomatic children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unkno

240 safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be r

241 The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be

242 r healthcare workers during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic

243 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic

244 Preliminary data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumoni

245 ur subtype, age, and sex and on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalen

246 lification for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in r

247 The availability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologi

248 g monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike pr

249 is infection of airway cells by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that res

250 and how the earliest sustained severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmis

251 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is

252 This pathogen, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes

253 ease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged

254 , and transmission dynamics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in orde

255 The causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a me

256 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cau

257 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the eti

258 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the eti

259 verity of the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the vir

260 f individuals who may carry the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while s

261 ying acute infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

262 tection of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

263 the natural immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

264 is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

265 nded following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

266 for exposure to infection with severe acute respiratory syndrome coronavirus 2 during the coronaviru

267 hria with positive findings for severe acute respiratory syndrome coronavirus 2 from nasopharyngeal s

268 tions have been associated with severe acute respiratory syndrome coronavirus 2 illness, but it remai

269 at myoclonus may be observed in severe acute respiratory syndrome coronavirus 2 infected patients, ev

270 virus disease 2019 out of 1,788 severe acute respiratory syndrome coronavirus 2 positive cases, rende

271 vents in patients infected with severe acute respiratory syndrome coronavirus 2 requiring venovenous

272 ng aerosols and splatters), for severe acute respiratory syndrome coronavirus 2 transmission, has cha

273 Polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 was positive in 33.6%

274 nding global pandemic caused by severe acute respiratory syndrome coronavirus 2, resulting in signifi

275 uent family members exposure to severe acute respiratory syndrome coronavirus 2.

276 vity against viruses, including severe acute respiratory syndrome coronavirus, human immunodeficiency

277 n Vero-E6 cells with SARS-CoV-2, Middle East respiratory syndrome CoV (MERS-CoV), bat CoV HKU5 expres

278 hat caused the 2002 outbreak of severe acute respiratory syndrome, including the system of cell entry

279 rocoagulant responses following severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infectio

280 to 18 years old with confirmed severe acute respiratory syndrome-CoV-2 disease who were admitted to

281 The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has

282 sease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2)

283 ysteresis, mechanical characteristics of the respiratory system, and lung recruitment assessed by a C

284 The respiratory system, which includes the trachea, airways,

285 at-Dx RP assay detected 312 (92%) of the 338 respiratory targets that were detected by the ePlex RPP

286 ading global cause of severe pediatric acute respiratory tract illness, and a vaccine is needed.

287 revalent ARI syndromes included: viral upper respiratory tract infection (47%), pharyngitis (18%), an

288 e of the significant pathogens causing acute respiratory tract infections in young children worldwide

289 was quantified in available upper- and lower-respiratory tract specimens as well as fecal and blood s

290 cell responses, whereas Aer induced powerful respiratory tract T cell responses but a low titer of Ab

291 infection (OR = 7.51; 95% CI = 4.37-12.91), respiratory tract viral infection (OR = 7.75; 95% CI = 1

292 ed oligosaccharide receptors to colonize the respiratory tract, but the contribution of the latter is

293 gens and unwanted surface materials from the respiratory tract, depends on the coordinated function o

294 the pathogenesis of S. aureus to include the respiratory tract.

295 loops, invasive pressures, diuretic output, respiratory variables, and blood analysis.

296 impact of a universal face masking policy on respiratory viral infections (RVIs) among admitted very-

297 The distribution of upper respiratory viral loads (VL) in asymptomatic children in

298 lower among patients who received an initial respiratory viral test.

299 ro diagnostic (IVD) real-time PCR assays for respiratory viruses, including an assay for influenza A

300 With respect to other cocirculating respiratory viruses, we found evidence of positive, rath